Clinical Evaluation of 755nm Alexandrite Laser Versus Nanosecond 755nm Alexandrite
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02130
- Boston VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is a healthy male or female between 18 and 85 years old?
- Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments
- Is willing to consent to participate in the study.
- Is willing to shield the tattoo completely from sun exposure
- Signs informed consent form
- Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits.
Exclusion Criteria:
- Subjects who are unwilling to consent to tattoos
- Subjects mentally ill or incompetent
- Subjects is unwilling to have photographs taken and used in publications or scientific presentations
- Subjects who are prisoners
- Subjects with recent sun exposure and suntan in the area to be treated
- Allergic tattoos (hypersensitivity to tattoo ink)
- History of vitiligo or keloidal scarring
- Tattoos located on the neck or face including cosmetic tattoos
- Subjects unwilling to tolerate partial removal of the tattoo in this study
- Infection or skin disease in the area to be treated
- Subjects who are immunosuppressed (e.g. HIV)
- Subject is pregnant or nursing
- Use of oral isotretinoin within past 12 months
- History of squamous cell carcinoma or melanoma
- Is allergic to Lidocaine, tetracaine or Xylocaine with epinephrine.
- Has any other reason determined by the physician to be ineligible to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 755nm Alexandrite Laser
|
755nm Alexandrite Laser
|
|
Experimental: Nanosecond 755nm Alexandrite Laser
|
755nm Alexandrite Laser
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Photographic Evaluation of Tattoo Clearance
Time Frame: up to 3 months post last treatment
|
up to 3 months post last treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subject biopsy sampling
Time Frame: up to 3 months post last treatment
|
Histological evaluation of tissue samples pre-treatment and post-treatment
|
up to 3 months post last treatment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with adverse events as a measure of safety and tolerability
Time Frame: up to 3 months post last treatment
|
up to 3 months post last treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CYN12-PICO_MGH_TB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.